Welcome to CRWENewswire, Stocks to watch. I am Sara Bryant. Sagent Pharmaceuticals Incorporated - symbol SGNT - reported FDA approval of Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Sagent’s latex-free clindamycin will be available in three single-dose vial sizes and in pharmacy bulk packaging. The company expects to launch the product in early 2012. According to IMS, the 2011 U.S. market for injectable clindamycin approximates $65 million. Sagent Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Thank you for joining me and stay with us! For CRWE Newswire, Stocks to Watch, I’m Sara Bryant
